Clinical trials: Melancholic Depression
Unipolar Depression
Transcranial Direct Current Stimulation for Depression
This study will test the efficacy of transcranial direct current stimulation (tDCS) combined with mindfulness, remotely-delivered using a telemedicine protocol in 25 adults with unipolar depression.
- Trial name
- NCT07042217
- Testing
- transcranial direct current stimulation (tDCS) and mindfulness instruction
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Soterix Medical
Respiratory Depression
ENA-001 for Opioid Induced Respiratory Depression
This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.
- Trial name
- NCT06967259
- Testing
- ENA-001
- Where
- 2 sites in United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Enalare Therapeutics Inc.
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an…
- Trial name
- SPARC-TMS (NCT07227103)
- Testing
- Neuronavigated robotic-enabled TMS, NRX-101
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder
Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)
The purpose of this study is to evaluate the effects of videogame-like digital therapies as adjunct therapy to antidepressant medications on cognitive deficits associated with major depressive disorder.
- Trial name
- NCT03310281
- Testing
- HOLD: Videogame
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Akili Interactive Labs, Inc.
Depression - Major Depressive Disorder, Anxiety
AcceXible Speech-Based Screening for Depression and Anxiety in University Students (BUAP, Mexico)
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD).
- Trial name
- NCT07553130
- Testing
- AcceXible
- Where
- Mexico
- Volunteers
- 785 people, healthy volunteers welcome
- Sponsor
- Accexible
Major Depressive Disorder (MDD)
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.
- Trial name
- NCT05018013
- Testing
- Ammoxetine hydrochloride enteric-coated tablets, Duloxetine hydrochloride enteric-coated capsules
- Where
- China
- Volunteers
- 240 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Major Depressive Disorder (MDD)
Validation of Accexible as a Tool for Screening and Monitoring Depression.
Major depressive disorder (MDD) is a chronic disease with a prevalence around 8-12% and is considered one of the most debilitating disease worldwide.
- Trial name
- NCT06044818
- Testing
- Accexible
- Where
- Spain
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Accexible
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Rheumatoid Arthritis
Changes of Depression After First-year of Tofacitinib in RA Patients
12-month, single arm, prospective, non-interventional, multi-center study according to Czech legal definitions (Law 378/2007 Sb.).The primary objective of this study is to describe and evaluate the changes of depression level…
- Trial name
- NCT03992781
- Where
- 6 sites in Czechia
- Volunteers
- 73 people
- Sponsor
- Pfizer
Major Depressive Disorder (MDD
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
The purpose of this study is to learn about: To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or…
- Trial name
- NCT07193901
- Testing
- Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray
- Where
- 15 sites in China
- Volunteers
- 98 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Treatment Resistant Depression
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
The primary objective of this study is to assess short, mid and long-term clinical outcomes in patients with difficult to treat depression (such as patients with treatment resistant depression) treated with Vagus Nerve…
- Trial name
- RESTORE-LIFE (NCT03320304)
- Testing
- Vagal Nerve Simulation (VNS) Therapy
- Where
- 18 sites in Austria, Belgium and 2 more
- Volunteers
- 500 people
- Sponsor
- LivaNova
Treatment Resistant Depression
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
The objective of this study is to collect both active and passive data using a wearable, multi-sensor device (Verily Study Watch) and phone application (Mood App) which aims to capture mental health status, in subjects…
- Trial name
- UNCOVER (NCT04753385)
- Where
- 33 sites in United States
- Volunteers
- 138 people
- Sponsor
- LivaNova
Treatment Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale…
- Trial name
- RECOVER (NCT03887715)
- Testing
- Vagus Nerve Stimulation (VNS)
- Where
- 101 sites in United States
- Volunteers
- 6,800 people
- Sponsor
- LivaNova
Postpartum Depression, Postnatal Depression
Phase 2 Clinical Trial of GH001 in Postpartum Depression
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 female participants with clinically diagnosed postpartum depression (PPD) will be included in this study.
- Trial name
- NCT05804708
- Testing
- GH001
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 10 people
- Sponsor
- GH Research Ireland Limited
Depression Disorders, Anxiety Disorders
Validate the Temporal Stability and Responsiveness of AI-COA® for Depression and Anxiety
This study evaluates the reliability and responsiveness of the AI-COA®, a digital tool designed to assess the severity of depression and anxiety.
- Trial name
- SEQUOIA-2 (NCT07279025)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Deliberate Solutions Inc.
Major Depressive Disorder
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
To evaluate, over a period of six months, the links between physiological data collected such as electrodermal activity (or Galvanic Skin Response), motor activity measured by accelerometer, heartbeat measured by…
- Trial name
- MYND104 (NCT05547035)
- Testing
- Patient follow-up of depression
- Where
- 11 sites in France
- Volunteers
- 200 people
- Sponsor
- Digital For Mental Health
Major Depressive Disorder
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371708
- Testing
- DVS SR
- Where
- 36 sites in United States, Chile
- Volunteers
- 283 people
- Sponsor
- Pfizer
Major Depressive Disorder
EEG Biomarkers for Predicting Response to Antidepressant Therapy
The purpose of this study is to evaluate the potential early EEG predictors of an individual's response to treatment with antidepressant medications.
- Trial name
- NCT00289523
- Where
- 10 sites in United States
- Volunteers
- 375 people
- Sponsor
- Medtronic - MITG
Pain, Depression
Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety
The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.
- Conditions
- Pain, Depression, Anxiety Disorder
- Trial name
- NCT00241397
- Where
- 91 sites in Belgium
- Volunteers
- 2,560 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, Major Depressive Episode
SAINT for MDD in an Inpatient Setting Follow-on
Randomized, multi-site, sham-controlled, double-blinded study
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
- Trial name
- NCT06462820
- Testing
- Active SAINT Stimulation
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Magnus Medical